Pfizer COVID-19 vaccine appointments are available to our patients. Sign up for Connect today to schedule your vaccination. Continue your routine care with us by scheduling an in-person appointment or Video Visit.

News

Therapeutic Metabolic Targets in Brain Cancer

Saturday, November 19, 2016

Howard Fine, M.D., recently spoke to OncLive about the importance of novel metabolic targets, such as IDH mutations, in the field of neuro-oncology. Mutations in IDH result in an altered metabolic state, in which production of the oncometabolite 2-HG is increased. This leads to dysregulation of genetic and epigenetic processes, leading to oncogenesis.

The metabolism of tumor tissue is very different from that in other tissue. That difference offers an area that can be used to develop more therapeutic targets. Although it is unlikely that another IDH-type mutations will be discovered, the differences between tumors and normal tissue are ideal targets, as inhibition of these markers would have less of an impact on healthy tissue, Fine notes

Tumor metabolism is very complex series of pathways, Fine notes. As the science advances, more knowledge will emerge on the molecular basis for the metabolic difference between tumor tissue and other tissue.